Propranolol and survival from breast cancer:a pooled analysis of European breast cancer cohorts

Autor:	Cardwell, Chris R., Pottegård, Anton, Vaes, Evelien, Garmo, Hans, Murray, Liam J., Brown, Chris, Vissers, Pauline A. J., O’Rorke, Michael, Visvanathan, Kala, Cronin-Fenton, Deirdre, De Schutter, Harlinde, Lambe, Mats, Powe, Des G., van Herk-Sukel, Myrthe P. P., Gavin, Anna, Friis, Søren, Sharp, Linda, Bennett, Kathleen
Jazyk:	angličtina
Rok vydání:	2016
Předmět:	Medicine(all) Adrenergic beta-Antagonists Cohort Angiogenesis Inhibitors Breast Neoplasms Propranolol Cohort Studies Europe Treatment Outcome Breast cancer SDG 3 - Good Health and Well-being Journal Article Humans Female Beta-blocker Mortality Research Article Proportional Hazards Models
Zdroj:	Cardwell, C R, Pottegård, A, Vaes, E, Garmo, H, Murray, L J, Brown, C, Vissers, P A J, O'Rorke, M, Visvanathan, K, Cronin-Fenton, D, De Schutter, H, Lambe, M, Powe, D G, van Herk-Sukel, M P P, Gavin, A, Friis, S, Sharp, L & Bennett, K 2016, ' Propranolol and survival from breast cancer : a pooled analysis of European breast cancer cohorts ', Breast Cancer Research (Online), vol. 18, no. 1, 119 . https://doi.org/10.1186/s13058-016-0782-5 Cardwell, C R, Pottegård, A, Vaes, E, Garmo, H, Murray, L J, Brown, C, Vissers, P A J, O'Rorke, M, Visvanathan, K, Cronin-Fenton, D, De Schutter, H, Lambe, M, Powe, D G, van Herk-Sukel, M P P, Gavin, A, Friis, S, Sharp, L & Bennett, K 2016, ' Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts ', Breast Cancer Research, vol. 18, no. 1, 119 . https://doi.org/10.1186/s13058-016-0782-5 Cardwell, C R, Pottegård, A, Vaes, E, Garmo, H, Murray, L J, Brown, C, Vissers, P A J, O'Rorke, M, Visvanathan, K, Cronin-Fenton, D, De Schutter, H, Lambe, M, Powe, D G, Herk-Sukel, M P P V, Gavin, A, Friis, S, Sharp, L & Bennett, K 2016, ' Propranolol and survival from breast cancer : A pooled analysis of European breast cancer cohorts ', Breast Cancer Research, vol. 18, no. 1, 119 . https://doi.org/10.1186/s13058-016-0782-5 Cardwell, C R, Pottegård, A, Vaes, E, Garmo, H, Murray, L J, Brown, C, Vissers, P A J, O'Rorke, M, Visvanathan, K, Cronin-Fenton, D, De Schutter, H, Lambe, M, Powe, D G, van Herk-Sukel, M P P, Gavin, A, Friis, S, Sharp, L & Bennett, K 2016, ' Propranolol and survival from breast cancer : a pooled analysis of European breast cancer cohorts ', Breast Cancer Research (Online Edition), vol. 18, no. 1, 119 . https://doi.org/10.1186/s13058-016-0782-5 Breast Cancer Research : BCR
DOI:	10.1186/s13058-016-0782-5
Popis:	BACKGROUND: Preclinical studies have demonstrated that propranolol inhibits several pathways involved in breast cancer progression and metastasis. We investigated whether breast cancer patients who used propranolol, or other non-selective beta-blockers, had reduced breast cancer-specific or all-cause mortality in eight European cohorts.METHODS: Incident breast cancer patients were identified from eight cancer registries and compiled through the European Cancer Pharmacoepidemiology Network. Propranolol and non-selective beta-blocker use was ascertained for each patient. Breast cancer-specific and all-cause mortality were available for five and eight cohorts, respectively. Cox regression models were used to calculate hazard ratios (HR) and 95% confidence intervals (CIs) for cancer-specific and all-cause mortality by propranolol and non-selective beta-blocker use. HRs were pooled across cohorts using meta-analysis techniques. Dose-response analyses by number of prescriptions were also performed. Analyses were repeated investigating propranolol use before cancer diagnosis.RESULTS: The combined study population included 55,252 and 133,251 breast cancer patients in the analysis of breast cancer-specific and all-cause mortality respectively. Overall, there was no association between propranolol use after diagnosis of breast cancer and breast cancer-specific or all-cause mortality (fully adjusted HR = 0.94, 95% CI, 0.77, 1.16 and HR = 1.09, 95% CI, 0.93, 1.28, respectively). There was little evidence of a dose-response relationship. There was also no association between propranolol use before breast cancer diagnosis and breast cancer-specific or all-cause mortality (fully adjusted HR = 1.03, 95% CI, 0.86, 1.22 and HR = 1.02, 95% CI, 0.94, 1.10, respectively). Similar null associations were observed for non-selective beta-blockers.CONCLUSIONS: In this large pooled analysis of breast cancer patients, use of propranolol or non-selective beta-blockers was not associated with improved survival.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::af684b7ca2898a5a5415756f2b09c994 https://findresearcher.sdu.dk:8443/ws/files/123648801/Propranolol_and_survival_from_breast_cancer.pdf Zobrazit plný text záznamu